## POST-TEST

Striving for Consensus: Current and Future Management of Immune Thrombocytopenia

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What is the mechanism of action of fostamatinib?
  - a. Thrombopoietin receptor agonist
  - b. SYK inhibitor
  - c. Anti-CD20 monoclonal antibody
  - d. Bruton tyrosine kinase inhibitor
- 2. Which of the following agents used in the management of immune thrombocytopenia (ITP) requires dietary restrictions to allow proper absorption?
  - a. Romiplostim
  - b. Rilzabrutinib
  - c. Avatrombopag
  - d. Eltrombopag
- 3. Which of the following symptoms is most commonly reported as severe among patients with ITP after diagnosis?
  - a. Blood in urine/stool
  - b. Hypotension
  - c. Fatigue
  - d. Persistent fever

- 4. Which of the following therapies used in the management of ITP is administered orally?
  - a. Rozanolixizumab
  - b. Rituximab
  - c. Avatrombopag
  - d. Romiplostim
- 5. Efgartigimod functions by binding to which of the following receptors?
  - a. Thrombopoietin receptor
  - b. Neonatal Fc receptor
  - c. B-cell receptor
  - d. Toll-like receptor 4